MedPacto Stock Forecast for 2023 - 2025 - 2030
Updated on 04/17/2024
MedPacto Fair Value Forecast for 2023 - 2025 - 2030
In the last year, MedPacto's Price has grown by 100.00%, rising from ₩0.00 to ₩0.00. For next year, analysts predict Fair Value of ₩0.00, which would mean an increase of 100.00%. Over the next six years, experts predict that MedPacto's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A207940 Stock Forecast | Samsung Biologics | Buy |
7
|
₩785.00k | Buy/Sell | ₩0.00B | 33.76% |
| A068270 Stock Forecast | Celltrion | Outperform |
16
|
₩172.00k | Buy/Sell | ₩215.28k | 27.91% |
| A091990 Stock Forecast | Celltrion Healthcare | Outperform |
12
|
₩75.90k | Buy/Sell | ₩90.17k | 15.94% |
| A196170 Stock Forecast | ALTEOGEN | Outperform |
6
|
₩168.30k | Buy/Sell | ₩83.33k | -16.82% |
| A068760 Stock Forecast | Celltrion Pharm | - |
11
|
₩90.00k | Buy/Sell | ₩11.33k | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A141080 Stock Forecast | LegoChem Biosciences | Outperform |
7
|
₩61.00k | Buy/Sell | ₩66.50k | 50.82% |
| A006280 Stock Forecast | GC Biopharma | Buy |
16
|
₩110.00k | Buy/Sell | ₩146.43k | 30.91% |
| A214370 Stock Forecast | Caregen | Outperform |
18
|
₩20.25k | Buy/Sell | ₩50.00k | 146.91% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A086900 Stock Forecast | Medy-Tox | Outperform |
8
|
₩132.30k | Buy/Sell | ₩335.00k | 179.67% |
| A007390 Stock Forecast | NatureCell | - |
0
|
₩7.29k | Buy/Sell | ₩0.00 | -100.00% |
| A256840 Stock Forecast | BNC Korea | - |
0
|
₩3.56k | Buy/Sell | ₩0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A298380 Stock Forecast | ABL Bio | Outperform |
6
|
₩22.05k | Buy/Sell | ₩37.00k | 67.80% |
| A214450 Stock Forecast | PharmaResearch | Outperform |
16
|
₩124.50k | Buy/Sell | ₩165.00k | 40.56% |
| A293780 Stock Forecast | AptaBio Therapeutics |
0
|
₩7.62k | Buy/Sell | ₩0.00 | -100.00% |
MedPacto EBITDA Forecast for 2023 - 2025 - 2030
MedPacto's EBITDA has seen impressive growth In the last two years, rising from ₩-26.36B to ₩-35.38B – a growth of 34.20%. For the following year, the 0 analysts predict that MedPacto's EBITDA will drop by 16.06%, reaching ₩-29.70B. In 2030, the professionals' prediction is that A235980's EBITDA will decrease by 14.74%, reaching ₩-30.17B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A182400 Stock Forecast | NKMAX CO. | - |
7
|
₩5.66k | Buy/Sell | ₩0.00 | -100.00% |
| A144510 Stock Forecast | GC Cell | - |
11
|
₩36.45k | Buy/Sell | ₩74.00k | -100.00% |
| A041960 Stock Forecast | Komipharm International | - |
6
|
₩4.39k | Buy/Sell | ₩0.00 | -100.00% |
MedPacto EBIT Forecast for 2023 - 2025 - 2030
In the last two years, MedPacto's EBIT has grown by 33.98%, rising from ₩-27.80B to ₩-37.25B. In the following year, the 0 analysts surveyed believe that MedPacto's EBIT will decrease by 15.82%, reaching ₩-31.35B. According to professionals, by 2030, MedPacto's EBIT will have decreased by 14.54%, falling down to ₩-31.83B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A065660 Stock Forecast | Anterogen.Co.,Ltd. | - |
7
|
₩14.01k | Buy/Sell | ₩0.00 | -100.00% |
| A115450 Stock Forecast | HLB Therapeutics | - |
6
|
₩12.03k | Buy/Sell | ₩20.77k | -100.00% |
| A290650 Stock Forecast | L&C Bio | - |
17
|
₩20.35k | Buy/Sell | ₩0.00 | -100.00% |
MedPacto EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, MedPacto's EPS has grown by 100.00%, rising from ₩-832.00 to ₩0.00. For next year, analysts predict EPS of ₩0.00, which would mean an increase of 100.00%. Over the next six years, experts predict that MedPacto's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A087010 Stock Forecast | Peptron | - |
6
|
₩22.75k | Buy/Sell | ₩35.00k | -100.00% |
| A031390 Stock Forecast | Green Cross Cell | - |
14
|
₩38.55k | Buy/Sell | ₩80.00k | -100.00% |
| A299660 Stock Forecast | Cellid, | - |
5
|
₩4.27k | Buy/Sell | ₩0.00 | -100.00% |
.jpg)